$Micromobility.com(MCOM.US)$ micromobility.com Inc. Slashes Debt by $9.25 Million in Strategic Financial Triumph
1 MINUTE AGO, 7:25 AM EST
VIA BUSINESSWIRE

$Affimed NV(AFMD.US)$ Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

$Intensity Therapeutics(INTS.US)$ Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
Benzinga· 08/24 08:521min
Intensity Therapeutics(INTS.US)
10.091
+152.28%
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 price target.
Disclaimer: This content is for informational and educational purposes only and does not constitute

$Phio Pharmaceuticals(PHIO.US)$ the best news i was waiting for 3 years

RBC Capital Sticks to Their Buy Rating for Viracta Therapeutics (VIRX)
RBC Capital analyst Gregory Renzamaintained a Buy rating on Viracta Therapeutics (VIRX – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $1.41.
According to TipRanks, Renza is a 4-star analyst with an average return of 8.7% and a 43.93% success rate. Renza covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, ACADIA Pharmaceuticals, and Verastem.
...

RBC Capital Sticks to Their Buy Rating for Viracta Therapeutics (VIRX)
RBC Capital analyst Gregory Renzamaintained a Buy rating on Viracta Therapeutics (VIRX – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $1.41.
According to TipRanks, Renza is a 4-star analyst with an average return of 8.7% and a 43.93% success rate. Renza covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, ACADIA Pharmaceuticals, and Verastem.
...

RBC Capital Sticks to Their Buy Rating for Viracta Therapeutics (VIRX)
RBC Capital analyst Gregory Renzamaintained a Buy rating on Viracta Therapeutics (VIRX – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $1.41.
According to TipRanks, Renza is a 4-star analyst with an average return of 8.7% and a 43.93% success rate. Renza covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, ACADIA Pharmaceuticals, and Verastem.
...

RBC Capital Sticks to Their Buy Rating for Viracta Therapeutics (VIRX)
RBC Capital analyst Gregory Renzamaintained a Buy rating on Viracta Therapeutics (VIRX – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $1.41.
According to TipRanks, Renza is a 4-star analyst with an average return of 8.7% and a 43.93% success rate. Renza covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, ACADIA Pharmaceuticals, and Verastem.
...

RBC Capital Sticks to Their Buy Rating for Viracta Therapeutics (VIRX)
RBC Capital analyst Gregory Renzamaintained a Buy rating on Viracta Therapeutics (VIRX – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $1.41.
According to TipRanks, Renza is a 4-star analyst with an average return of 8.7% and a 43.93% success rate. Renza covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, ACADIA Pharmaceuticals, and Verastem.
...